Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
  • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
  • A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
  • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
  • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/04—Immunostimulants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
  • A61K2039/55511—Organic adjuvants
  • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Definitions

• the present invention is in the field of pharmaceutical compositions, particularly in the field of vaccines. More specifically, the subject of the invention is a novel pharmaceutical composition that can be used as a vaccine (or vaccine composition).
• the invention also relates to a process for preparing said vaccine composition according to the invention.
• Vaccine adjuvants have been known for a long time and are defined as compositions which, when combined with an antigen, produce an immune response superior to that of the antigen alone.
• the immunogenicity of a non-adjuvanted vaccine is generally low, especially if it is an inactivated vaccine or if the antigen is simply a peptide or protein, and does not in itself allow induce a protective response.
• Alum phosphate and aluminum hydroxide
• Alum is an adjuvant that is widely used in human and veterinary vaccines.
• adjuvants are known and used for research such as Freund's adjuvant consisting of a mixture of mineral oil and killed mycobacteria. This adjuvant is extremely effective and produces marked immune responses. Its poor tolerance, however, limits its use to research on laboratory animals.
• U.S. Patent No. 4,788,056 discloses a combination vaccine against herpes and E. coli for vaccination of livestock.
• This patent mentions various possible adjuvants, among which emulsions of oil in water or water in oil based on certain oils such as Miglyol® (medium chain triglycerides) or surfactants such as polysorbate, without, however, indicating a precise formulation of the adjuvant.
• these are conventional emulsions in which the dispersed phase exists in the form of droplets.
• none indication is not given as to the effect of the adjuvant on the immunogenicity of the vaccine.
• U.S. Patent No. 5,688,761 discloses a water-in-oil microemulsion formulation that converts to an oil-in-water system by adding an aqueous fluid which results in the release of the protein contained in the aqueous phase.
• the advantage of microemulsions is their spontaneous formation and their physical stability.
• the oils used by these authors are well-tolerated oils for injection such as medium-chain mono and triglycerides. They are emulsified in the aqueous phase by the use of conventional surfactants and known to those skilled in the art such as sorbitan esters or polysorbates. Their dilution by the biological fluids during their injection causes the inversion of the phases and thus the release of the biological agent incorporated in the aqueous phase.
• Some formulation examples demonstrate an increase in the activity of biological agents incorporated in the described formulation. However, the examples provided do not relate to the field of vaccines.
• US Pat. No. 5,744,137 describes the use of non-mineral oils in vaccines as well as vaccines in the form of water-in-oil emulsions containing a mixture of at least two surfactants chosen from ethoxylated castor oil, laurate propylene glycol, propylene glycol caprylate and isosteryl diglyceryl succinate.
• the oils chosen are of animal or vegetable origin in order to limit as much as possible the tissue reaction linked to the administration of poorly tolerated mineral oils.
• U.S. Patent No. 5,961,970 discloses a vaccine adjuvant in the form of an oil-in-water submicroemulsion comprising an emulsifier (it is a phospholipid), a nonionic surfactant, and an oil. The high cost of phospholipids limits however the applications of this invention.
• U.S. Patent Application No. 2003011977 discloses a biphasic lipid vesicle composition for enhancing the immune response induced by an antigen.
• U.S. Patent Application No. 20030175309 discloses an adjuvant containing lecithin, an oil and an amphiphilic surfactant capable of forming a vaccine in the form of a stable oil-in-water emulsion which minimizes local reactions in the injected animal.
• European Patent Application No. 0 398 287 discloses a pharmaceutical composition in the form of an isotropic solution consisting of one or more active substances and a support which solidifies at between 20 ° C. and 80 ° C. (particularly at room temperature) and being soluble in water. Nevertheless, there is a continuing need in the vaccine industry for new adjuvants having the properties set forth above. In particular, the need remains to provide adjuvants allowing a strong increase of immunogenicity of the antigen. An advantage of such adjuvants lies in the fact that they allow to administer reduced doses of antigen while maintaining a satisfactory immune response. It is particularly desirable to have such compositions when the antigen is expensive or difficult to produce in sufficient amount or when it is a simple peptide or antigens obtained by synthesis or recombination.
• a pharmaceutical composition in the form of an oily isotropic at least composed of a ternary mixture oil / surfactant (s) / aqueous phase, said aqueous phase comprising the antigenic substance , could have a much higher immunogenicity than a ternary composition of the prior art in the form of an emulsion, in a non-isotropic form.
• a composition in an isotropic form may have a viscosity compatible with injection use.
• isotropic will be used hereinafter to designate the oily isotropic according to the invention, that is to say the ternary isotropic mixture oil / surfactant (s) / aqueous phase according to the invention.
• isotropic comprising an antigenic substance will denote a composition according to the invention in which the antigenic substance is included in the aqueous phase of the isotropic oily according to the invention.
• oily isotropic is meant a mixture of oil, water and surfactants whose proportions are adjusted so that the preparation obtained is clear, clear and has a low viscosity.
• Such a composition corresponds to a solubilization of water in an oil, or more precisely water in a micelle, itself in an oil (isotropic oily).
• micelles molecular aggregates of surfactants
• Isotropes are well known and all necessary information can be found among others in Galenica, 1983, Vol. 5, Chapter 5, page 195-219.
• this work presents ternary water / oil / surfactant diagrams, for example on page 203 a water / oil paraffin / Brij 96 diagram, making it possible to determine the respective concentrations of these compounds for which an isotropic system is obtained.
• a composition in isotropic form has a continuous three-dimensional structure, also called monophasic structure.
• the emulsions for their part are formed by a system of two immiscible liquids, one of which is finely divided into droplets, or vesicles, in the other.
• the dispersed phase is called internal phase or discontinuous, the dispersant phase is called external phase or continuous.
• An emulsion is therefore a liquid-liquid dispersion, which has a biphasic structure.
• a composition in isotropic form is distinguished from an emulsion by the absence of vesicle type organization and the presence of micelles.
• vesicle-type organization is intended to mean a structure having a wall comprising, or consisting of, surfactant-type components, said wall including a volume comprising, or constituted by, a hydrophilic internal phase when the outer phase is hydrophobic and vice versa.
• the invention therefore firstly relates to a pharmaceutical composition
• a pharmaceutical composition comprising at least one mixture of at least one oil, at least one surfactant and an aqueous phase comprising itself at least one active substance, said pharmaceutical composition being under the oily isotropic form.
• This composition is in isotropic form, it is therefore not in the form of an emulsion.
• the composition has a viscosity compatible with injection use.
• the active substance may be any type of biological active agent such as, for example, a live, attenuated or inactivated antigen.
• living antigen is meant a bacterium or a virus attenuated empirically or genetically, a protein antigen (or glycoprotein). lipoprotein) expressed in vivo by a vector (bacterium or recombinant virus).
• inactivated antigen an inactivated bacterium or virus either by physical methods or by chemical methods or a bacterial or viral extract, or a protein, a polypeptide or a peptide obtained by genetic recombination or by chemical synthesis, or at least one in vivo generator of a compound comprising an amino acid sequence.
• Especially the biological asset can be inert.
• the pharmaceutical composition is a vaccine.
• the active substance is then an antigen.
• Said antigen may be of any origin and in any form commonly used in the field of vaccination.
• the antigen may be, for example, of viral, bacterial, parasitic or even tumor origin.
• the antigen can be natural or recombinant. It may be composed of a microorganism (virus, bacteria or parasites), possibly attenuated or inactivated, or fractions, particularly acellular, of said microorganism (purified antigens, proteins or glyco-proteins or native peptides, polynucleotides, whether they are synthesis or produced by genetic engineering in particular), or based on hydro-soluble or water-dispersible antigens.
• a microorganism virus, bacteria or parasites
• fractions, particularly acellular, of said microorganism purified antigens, proteins or glyco-proteins or native peptides, polynucleotides, whether they are synthesis or produced by genetic engineering in particular
• hydro-soluble or water-dispersible antigens based on hydro-soluble or water-dispersible antigens.
• an antigenic phase composed of molecules excreted by said microorganism will be used, whether they be components of the bacterial wall or components of the cytoplasm.
• the amount of active substance and / or antigen in the composition according to the invention is a function of the desired effect and of the very nature of the active substance or antigen used. The skilled person knows depending on the active substance or the antigen used to dose it.
• the concentration of surfactant may be greater than the critical micelle concentration (CMC).
• CMC critical micelle concentration
• the value of the CMC can be determined by various methods, for example conductimetry or spectrophotometry, especially as described in the article by Dominguez et al., Journal of Chemical Education, 1997, 1227-1231.
• the CMC corresponds to a sudden change in the law of variation of the measured parameter, for example, conductance or absorbance.
• the compositions according to the invention may comprise a surfactant content greater than or equal to the critical micelle concentration. This critical micellar concentration depends on several parameters, including the nature of the components present in the composition and their content.
• composition according to the invention will comprise at least a high concentration of surfactant and a small amount of water.
• the composition may comprise from 10% to 90% of an oil, preferably from 40% to 75% by weight, relative to the weight of the total composition.
• the amount of water in the composition will be between 0.5% and 20%, preferably between 3% and 9% by weight, relative to the weight of the total composition.
• the amount of surfactant in the composition may be between 1% to 60%, preferably between 16% and 45% by weight, relative to the weight of the total composition.
• the ratio of the amount of oil to the amount of water must not be less than 1 (amount of oil equal to the amount of water), preferably not less than 5 (amount of oil). oil at least 5 times larger than the amount of water).
• Many oils can be used in the composition according to the invention. However, said oil must be compatible with a pharmaceutical use, particularly for use by parenteral injection.
• the oil may be chosen from: mineral oils, such as and not limited to paraffin oil, liquid petroleum jelly, non-mineral oils, such as cod liver oil, synthetic lipids, oils (such as without limitation soybean oil, olive oil, corn oil, peanut oil, cottonseed oil, sunflower oil, oil sesame, castor oil, almond oil), medium and long chain triglycerides (such as triglycerides of caprylic / capric acids such as those sold by Stearineries Dubois or those sold under the names Miglyol 810® 812® and 818® by Dynamit Nobel), terpene oils such as squalane and squalene, and mixtures thereof.
• mineral oils such as and not limited to paraffin oil, liquid petroleum jelly, non-mineral oils, such as cod liver oil, synthetic lipids, oils (such as without limitation soybean oil, olive oil, corn oil, peanut oil, cottonseed oil, sunflower oil, oil sesame, castor oil, almond oil), medium and long chain triglycerides (such
• an oil such as squalene or, preferably, an oil of the triglyceride family and very preferably medium chain triglycerides of the Mygliol 810 type.
• an oil mixture can be used.
• the surfactants that can be used according to the invention can be anionic, cationic, nonionic or amphoteric.
• the preferred class because of its good tolerance, particularly during an injection, is that of the nonionic surfactants.
• all those that can be used by the injectable route can be used alone or as a mixture.
• polysorbates sorbitan esters, particularly sorbitan esters of fatty acids, polyoxyethylenated derivatives of castor oil, polyoxyethylenated derivatives of the acid, stearic acids, copolymers of ethylene oxide and 1 propylene oxide or poloxamers, sucrose esters of fatty acids, glycol esters of fatty acids, mono-, di- and tri- esters fatty acid and glycerol, esters of polyethylene glycols and fatty acids, esters of sucrose and fatty acids.
• the polysorbates, the sorbitan esters, in particular the sorbitan and fatty acid esters are used.
• These surfactants may have identical or different HLBs (hydrophilic-lipophilic balance which is a characteristic of surfactants, linked to the structure of their molecule).
• the surfactants will have different HLBs so as to approach the critical HLB of the oily phase used.
• Critical HLB is a function of the concentration of emulsifiers and the chemical nature of the surfactants.
• HLB surfactants can therefore, depending of the composition of the mixture that it wishes to achieve, choose the appropriate surfactant (s).
• the aqueous phase may contain, besides the water-soluble or water-dispersible antigen and water, other substances such as salts intended to complex The antigen so as to delay its release and thus to prolong its action.
• salts include alumina silicate or calcium phosphate.
• the aqueous phase may also optionally contain non-specific immunogenic substances known to those skilled in the art, such as lipopolysaccharide or chitosan. Similarly, it may contain polymers, nonionic copolymers (such as, for example, poloxamer), synthetic clay (for example Laponite®, Chimilab Essor), cytokines, or antioxidants such as vitamin E, which are recognized for their immunostimulant power.
• the composition has a viscosity of between 5 and 150 mPa.s, preferably between 5 and 100 mPa.s.
• the viscosity of the composition is measured at ambient temperature, preferably at 25 ° C., using a rotor-stator type viscometer, such as, for example, an apparatus of the Rhéo brand called HAAK-VT500, according to the manufacturer's instructions.
• a rotor-stator type viscometer such as, for example, an apparatus of the Rhéo brand called HAAK-VT500, according to the manufacturer's instructions.
• composition according to the invention may be prepared according to any procedure known to those skilled in the art.
• a composition according to the invention may be prepared according to the following procedure:
• the antigen in a first step, is dissolved or dispersed in the aqueous phase in which the additional substances described above are also optionally incorporated and the mixture is heated, for example in a water bath, at a temperature of between 30 and 60 0 C, preferably between 35 and 45 ° C;
• the surfactant or surfactants are mixed with the oil and the mixture is heated, for example in a water bath, at a temperature of between 30 and 60 ° C., preferably between 35 and 45 ° C .;
• the aqueous phase is incorporated into the oily phase by using a homogenizer (such as, for example, a Rayneri® 33300 homogenizer).
• a homogenizer such as, for example, a Rayneri® 33300 homogenizer.
• these devices are widely used, particularly in the preparation of emulsions, and the skilled person will have no difficulty in carrying out the mixture according to the invention; and in a final step, the oily isotropic product obtained is cooled to room temperature and sterilized.
• Various methods described in the literature can be used for this operation such as, for example, sterilization by heat, ionizing radiation or by filtration. The preferred mode of doing is that of sterilizing filtration.
• the same aqueous phase containing the antigen is used. It is an acellular antigenic phase composed of antigens excreted during the cultivation of a bacterial strain of Streptococcus suis. This bacterium is responsible for a severe and widespread pathology in piglets. The infection is characterized by nervous disorders (motor incoordination, tremors, convulsions) and articular disorders. Septicemia has also been reported, as well as pulmonary lesions. A transmission to humans is possible (slaughterhouse staff, veterinarians).
• the MRP protein Muramidase Released Protein
• ELISA Enzyme-Linked Immunosorbent Assay
• the aliquot of stock solution containing the desired amount of antigens is diluted to the necessary and sufficient amount of a buffer usually used in the field of vaccines, such as for example phosphate buffer.
• a buffer usually used in the field of vaccines such as for example phosphate buffer.
• Example 2 Composition 1 The following table shows the composition according to the invention which is produced. Quantities are given in grams.
• Miglyol 810®, Tween 80 and Span 80 are mixed.
• the oily phase obtained is heated in a water bath at 40 ° C.
• the aqueous phase is also heated at 40 ° C. in a water bath
• the aqueous phase is added dropwise to the oily phase by homogenizing with a turbine mixer (Rayneri 33300) rotating at 500 rpm.
• the two beakers are maintained at 40 ° C.
• the mixture is made, it is removed from the water bath and allowed to cool to room temperature.
• the target MRP protein title of the finished product is
• the target title is a title to a reference antigen with a theoretical and arbitrary titer of 1. (1.6 means that the vaccine has a titre 1.6 times higher than the reference used).
• the target MRP protein titre of the finished product is 1.6.
• Miglyol 810® Tween 80® and Span 80® are mixed. This mixture is sterilized by heating at 120 ° C. for 30 minutes and then allowed to cool to room temperature.
• the aqueous phase containing the antigen is sterilized by filtration on a synthetic membrane of 0.22 ⁇ m porosity.
• the oily phase obtained above and the aqueous phase prepared in Example 1 are heated in parallel and separately in a water bath at 40 ° C.
• the aqueous phase is added dropwise to the phase oily by homogenizing with a turbine mixer (Rayneri 33300) rotating at 500 rpm.
• both beakers are kept at temperature. Once the mixture is made, it is removed from the water bath and allowed to cool to room temperature.
• the target MRP protein titre of the finished product is 1.6.
• composition 1 of Example 2 The activity of the composition 1 of Example 2 is compared with that of other compositions of the prior art comprising one or more adjuvants described in the literature and known to those skilled in the art.
• Formulation Control 1 oil-in-water type emulsion:
• Example 2 For this emulsion, the same excipients described for the oily isotropic of Example 2 were used in different proportions to obtain a very fine emulsion, for a critical HLB of 11. The amounts are given in grams.
• the antigenic phase obtained in Example 1 is sterilized by filtration on a synthetic membrane with a porosity of 0.22 ⁇ m.
• Miglyol®, Tween 80® and Span 80® are mixed and the mixture is sterilized by heating at 120 ° C. for 30 minutes and allowed to cool to room temperature.
• aqueous phase (antigen phase) and the oily phase are then heated separately at 40 ° C. in a water bath.
• the aqueous phase is added to the oily phase with stirring at 3000 rpm.
• Formulation Control 2 adjuvant oil-in-water (Montanide IMS, SEPPIC)
• Example 1 The aqueous phase obtained in Example 1 and the adjuvant are mixed with stirring using the Rayneri T33300 homogenizer rotating at 150 rpm for 20 seconds.
• Formulation Control 3 adjuvant of water / oil trade (Montanide ISA 763 VG, SEPPIC)
• the aqueous phase, obtained in Example 1, is filtered through a 0.22 ⁇ m nylon filter, the PTFE filter adjuvant of 0.22 ⁇ m porosity, the assembly being aseptically assembled.
• the adjuvant is placed in a beaker with stirring at 800 rpm using a Rayneri T33300 homogenizer.
• the antigenic aqueous phase is incorporated all at once, with stirring at 1200 rpm, maintained for 30 minutes.
• Formulation Control 4 adjuvant water in oil (Montanide ISA 563 VG, SEPPIC)
• the aqueous part of the formulation is filtered on 0.22 ⁇ m nylon filter, adjuvant on PTFE filters of 0.22 ⁇ m porosity, the assembly being assembled aseptically.
• the adjuvant is placed in a beaker and stirred at 800 rpm using a Rayneri T33300 homogenizer.
• the antigenic aqueous phase is incorporated all at once, with stirring at 1200 rpm, maintained for 15 minutes.
• Control formulation 5 LH adjuvant according to patent application WO 01/40240
• aqueous adjuvant LH is sterilized by the supplier and received as is. Aseptically, the aqueous antigenic phase and the salt buffer are mixed by magnetic stirring for 5 to 10 min., Then the LH adjuvant is added very slowly ("meshed") to the antigenic-salt buffer mixture. Stirring is maintained for 10 minutes.
• the MRP protein titers, measured as previously described, control formulations are about 4 (in RP units, (Relative Potency: Unit of Measure by Relative Potency Calculation Software, version 3.0, US Department of Agriculture). That of the composition according to the invention is 1.01.
• the comparison of the tolerance and the immunogenic activity is carried out on the mouse.
• mice BALB / C mice (supplier: Charles River) of 18-22 grams at the reception received, 2 weeks apart, 2 injections of 250 ⁇ l intraperitoneally. Blood was collected one week after the booster at autopsy of the mice. From a serological point of view, the level of anti-Streptococcus suis antibodies was evaluated by an ELISA method.
• the wells of a micro-plate are lined with the antigen (acellular supernatant of the culture) and then saturated.
• the sera of the mice which received the vaccine are diluted and deposited in the plate.
• a labeled anti-mouse antibody (enzyme conjugated) is added.
• the substrate / chromogen of the enzyme is deposited and the reaction colored is measured.
• the immunogenic activity of each composition is then defined by an average titre (in RP) corresponding to the mean of the titers of the mice making up the group.
• Tolerance is assessed according to three criteria: the mortality rate, the activity of the animal and the appearance of the coat. The presence of a residue at the injection point is also verified.
• the values indicated are relative: the value indicated represents the immunogenic capacity of a composition according to the invention relative to the immunogenic capacity of the control No. 5 which was used as a reference for the evaluation of the immunogenic power of each tested control.
• composition 1 which contains 4 and 6 times less antigen than the controls 1 to 4, induces an immunological response between 2 and 80 times higher than that induced by these same controls. • tolerance in animals
• composition 5 is perfectly tolerated both locally and systemically, and much better tolerated than the 4 control formulas.

Applications Claiming Priority (2)

Publications (1)

Family

ID=34952132

Family Applications (1)

Country Status (17)

Families Citing this family (1)

Citations (1)

Family Cites Families (22)

• 2004
  • 2004-12-02 FR FR0452838A patent/FR2878746B1/fr not_active Expired - Fee Related
• 2005
  • 2005-12-01 US US11/792,122 patent/US8158133B2/en not_active Expired - Fee Related
  • 2005-12-01 MX MX2007006521A patent/MX2007006521A/es active IP Right Grant
  • 2005-12-01 UA UAA200707275A patent/UA91203C2/ru unknown
  • 2005-12-01 AU AU2005311188A patent/AU2005311188B2/en not_active Ceased
  • 2005-12-01 CA CA002589841A patent/CA2589841A1/fr not_active Abandoned
  • 2005-12-01 KR KR1020077015073A patent/KR20070106988A/ko not_active Application Discontinuation
  • 2005-12-01 WO PCT/FR2005/002995 patent/WO2006059009A1/fr active Application Filing
  • 2005-12-01 EP EP05824496A patent/EP1817053A1/de not_active Withdrawn
  • 2005-12-01 NZ NZ555743A patent/NZ555743A/en not_active IP Right Cessation
  • 2005-12-01 CN CNA2005800475531A patent/CN101111262A/zh active Pending
  • 2005-12-01 BR BRPI0517124-5A patent/BRPI0517124A/pt not_active IP Right Cessation
  • 2005-12-01 JP JP2007543883A patent/JP4987725B2/ja not_active Expired - Fee Related
  • 2005-12-01 EA EA200701201A patent/EA200701201A1/ru unknown
• 2007
  • 2007-05-29 IL IL183518A patent/IL183518A/en not_active IP Right Cessation
  • 2007-06-12 ZA ZA200705079A patent/ZA200705079B/xx unknown
  • 2007-06-28 NO NO20073333A patent/NO20073333L/no not_active Application Discontinuation

Patent Citations (1)

Also Published As

Similar Documents

Legal Events